[{"orgOrder":0,"company":"Pfenex","sponsor":"Serum Institute of India Private Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"CRM197","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pfenex \/ Serum Institute of India Private Limited","highestDevelopmentStatusID":"10","companyTruncated":"Pfenex \/ Serum Institute of India Private Limited"},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ Not Applicable"},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0.52000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Pfenex \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Pfenex","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Pfenex","amount2":0.52000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.52000000000000002,"dosageForm":"","sponsorNew":"Pfenex \/ Ligand","highestDevelopmentStatusID":"3","companyTruncated":"Pfenex \/ Ligand"}]

Find Clinical Drug Pipeline Developments & Deals by Pfenex

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Ligand gains a proprietary platform which uses P. fluorescens bacterium, which are especially well-suited for complex, large-scale protein production that cannot be made by more traditional host systems.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : $438.0 million

                          October 01, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $516.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Acquisition of Pfenex is expected to contribute a range of strategic benefits to Ligand like access to a proprietary, protein expression technology, utilized in various commercial and development-stage biopharmaceutical programs. Versatile operating busi...

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : $438.0 million

                          August 10, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $516.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Pfenex received a positive opinion for PF708 (branded in Europe as Livogiva™) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

                          Brand Name : Livogiva

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          June 26, 2020

                          Lead Product(s) : Teriparatide

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Pfenex is eligible to receive annual fees, milestone payments, and royalty based on net sales for all products developed by Serum Institute that use the CRM197 produced via Pfenex Expression Technology.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 08, 2020

                          Lead Product(s) : CRM197

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Serum Institute of India Private Limited

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank